메뉴 건너뛰기




Volumn 36, Issue 10, 2016, Pages 5019-5024

Histone deacetylase inhibitors: A novel therapeutic weapon gainst medullary thyroid cancer?

Author keywords

Acetylasation; Cancer; Epigenetics; HDAC; Histone; Inhibitors; Medullary; Review; Targeted; Therapy; Thyroid

Indexed keywords

BELINOSTAT; BUTYRIC ACID; BUTYRIC ACID DERIVATIVE; DEPSIPEPTIDE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; M CARBOXYCINNAMIC ACID BIS HYDROXAMINE; SUBEROYL BIS HYDROXAMIC ACID; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

EID: 84991769523     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: 10.21873/anticanres.11070     Document Type: Review
Times cited : (28)

References (41)
  • 2
    • 84944909595 scopus 로고    scopus 로고
    • Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma
    • Raue F and Frank-Raue K: Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma. Recent Results Cancer Res 204: 61-90, 2015.
    • (2015) Recent Results Cancer Res , vol.204 , pp. 61-90
    • Raue, F.1    Frank-Raue, K.2
  • 5
    • 77949490246 scopus 로고    scopus 로고
    • Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride
    • Adler JT, Hottinger DG, Kunnimalaiyaan M and Chen H: Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride. J Surg Res 159: 640-644, 2010.
    • (2010) J Surg Res , vol.159 , pp. 640-644
    • Adler, J.T.1    Hottinger, D.G.2    Kunnimalaiyaan, M.3    Chen, H.4
  • 6
    • 79251524248 scopus 로고    scopus 로고
    • Alternative therapeutic approaches in the treatment of primary and secondary dedifferentiated and medullary thyroid carcinoma
    • Biermann K, Biersack HJ, Sabet A and Janzen V: Alternative therapeutic approaches in the treatment of primary and secondary dedifferentiated and medullary thyroid carcinoma. Semin Nucl Med 41: 139-148, 2011.
    • (2011) Semin Nucl Med , vol.41 , pp. 139-148
    • Biermann, K.1    Biersack, H.J.2    Sabet, A.3    Janzen, V.4
  • 9
    • 84875347365 scopus 로고    scopus 로고
    • Treatment of advanced medullary thyroid cancer
    • Smit J: Treatment of advanced medullary thyroid cancer. Thyroid Res 6(Suppl 1): S7, 2013.
    • (2013) Thyroid Res , vol.6 , pp. S7
    • Smit, J.1
  • 10
  • 11
    • 84874824354 scopus 로고    scopus 로고
    • Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma
    • Giunti S, Antonelli A, Amorosi A and Santarpia L: Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma. Int J Endocrinol 2013: 803171, 2013.
    • (2013) Int J Endocrinol , vol.2013 , pp. 803171
    • Giunti, S.1    Antonelli, A.2    Amorosi, A.3    Santarpia, L.4
  • 14
    • 84893713574 scopus 로고    scopus 로고
    • Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions
    • Giaginis C, Alexandrou P, Delladetsima I, Giannopoulou I, Patsouris E and Theocharis S: Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions. Tumour Biol 35: 61-71, 2014.
    • (2014) Tumour Biol , vol.35 , pp. 61-71
    • Giaginis, C.1    Alexandrou, P.2    Delladetsima, I.3    Giannopoulou, I.4    Patsouris, E.5    Theocharis, S.6
  • 16
    • 84855471990 scopus 로고    scopus 로고
    • HDAC inhibitors in cancer biology: Emerging mechanisms and clinical applications
    • Khan O and La Thangue NB: HDAC inhibitors in cancer biology: Emerging mechanisms and clinical applications. Immunol Cell Biol 90: 85-94, 2012.
    • (2012) Immunol Cell Biol , vol.90 , pp. 85-94
    • Khan, O.1    La Thangue, N.B.2
  • 17
    • 70349100446 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors: Current status and overview of recent clinical trials
    • Ma X, Ezzeldin HH and Diasio RB: Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 69: 1911-1934, 2009.
    • (2009) Drugs , vol.69 , pp. 1911-1934
    • Ma, X.1    Ezzeldin, H.H.2    Diasio, R.B.3
  • 18
    • 77649171884 scopus 로고    scopus 로고
    • Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
    • Tan J, Cang S, Ma Y, Petrillo RL and Liu D: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 3: 5, 2010.
    • (2010) J Hematol Oncol , vol.3 , pp. 5
    • Tan, J.1    Cang, S.2    Ma, Y.3    Petrillo, R.L.4    Liu, D.5
  • 19
    • 84959120824 scopus 로고    scopus 로고
    • Histone deacetylase (HDAC)-1,-2,-4 and-6 expression in human pancreatic adenocarcinoma: Associations with clinicopathological parameters, tumor proliferative capacity and patients' survival
    • Giaginis C, Damaskos C, Koutsounas I, Zizi-Serbetzoglou A, Tsoukalas N, Patsouris E, Kouraklis G and Theocharis S: Histone deacetylase (HDAC)-1,-2,-4 and-6 expression in human pancreatic adenocarcinoma: Associations with clinicopathological parameters, tumor proliferative capacity and patients' survival. BMC Gastroenterol 15: 148, 2015.
    • (2015) BMC Gastroenterol , vol.15 , pp. 148
    • Giaginis, C.1    Damaskos, C.2    Koutsounas, I.3    Zizi-Serbetzoglou, A.4    Tsoukalas, N.5    Patsouris, E.6    Kouraklis, G.7    Theocharis, S.8
  • 20
    • 73949128107 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors in cancer therapy
    • Lane AA and Chabner BA: Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27: 5459-5468, 2009.
    • (2009) J Clin Oncol , vol.27 , pp. 5459-5468
    • Lane, A.A.1    Chabner, B.A.2
  • 21
    • 81555228390 scopus 로고    scopus 로고
    • Belinostat: Clinical applications in solid tumors and lymphoma
    • Molife LR and de Bono JS: Belinostat: Clinical applications in solid tumors and lymphoma. Expert Opin Investig Drugs 20: 1723-1732, 2011.
    • (2011) Expert Opin Investig Drugs , vol.20 , pp. 1723-1732
    • Molife, L.R.1    De Bono, J.S.2
  • 22
    • 84991832873 scopus 로고    scopus 로고
    • National Institutes of Health (NIH), Clinical Trials
    • National Institutes of Health (NIH), Clinical Trials. Available at: http://www.clinicaltrials.gov.
  • 23
    • 85013006897 scopus 로고    scopus 로고
    • Induction of apoptosis and autophagy in metastatic thyroid cancer cells by valproic acid (VPA)
    • Xu Y, Xu D, Zhu SJ, Ye B, Dong JD, Zhang YL and Zhang Y: Induction of apoptosis and autophagy in metastatic thyroid cancer cells by valproic acid (VPA). Int J Clin Exp Pathol 8: 8291-8297, 2015.
    • (2015) Int J Clin Exp Pathol , vol.8 , pp. 8291-8297
    • Xu, Y.1    Xu, D.2    Zhu, S.J.3    Ye, B.4    Dong, J.D.5    Zhang, Y.L.6    Zhang, Y.7
  • 24
    • 35448983934 scopus 로고    scopus 로고
    • Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC)
    • Provenzano MJ, Fitzgerald MP, Krager K and Domann FE: Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC). Otolaryngol Head Neck Surg 137: 722-728, 2007.
    • (2007) Otolaryngol Head Neck Surg , vol.137 , pp. 722-728
    • Provenzano, M.J.1    Fitzgerald, M.P.2    Krager, K.3    Domann, F.E.4
  • 26
    • 84885400899 scopus 로고    scopus 로고
    • Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment
    • Lin SF, Lin JD, Chou TC, Huang YY and Wong RJ: Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment. PLoS One 8: e77684, 2013.
    • (2013) PLoS One , vol.8 , pp. e77684
    • Lin, S.F.1    Lin, J.D.2    Chou, T.C.3    Huang, Y.Y.4    Wong, R.J.5
  • 27
    • 35448983934 scopus 로고    scopus 로고
    • Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC)
    • Provenzano MJ, Fitzgerald MP and Domann FE: Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC). Otolaryngol Head Neck Surg 137: 722-728, 2007.
    • (2007) Otolaryngol Head Neck Surg , vol.137 , pp. 722-728
    • Provenzano, M.J.1    Fitzgerald, M.P.2    Domann, F.E.3
  • 28
    • 0038676409 scopus 로고    scopus 로고
    • Inhibition of histone deacetylase activity by butyrate
    • Davie JR: Inhibition of histone deacetylase activity by butyrate. J Nutr 133(7 Suppl): 2485S-2493S, 2003.
    • (2003) J Nutr , vol.133 , Issue.7 , pp. 2485S-2493S
    • Davie, J.R.1
  • 29
    • 0032500865 scopus 로고    scopus 로고
    • Role of butyric acid and its derivatives in the treatment of colorectal cancer and hemoglobinopathies
    • Pouillart PR: Role of butyric acid and its derivatives in the treatment of colorectal cancer and hemoglobinopathies. Life sciences 63: 1739-1760, 1998.
    • (1998) Life Sciences , vol.63 , pp. 1739-1760
    • Pouillart, P.R.1
  • 30
    • 79960087121 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors upregulate Rap1GAP and inhibit Rap activity in thyroid tumor cells
    • Dong X, Korch C and Meinkoth JL: Histone deacetylase inhibitors upregulate Rap1GAP and inhibit Rap activity in thyroid tumor cells. Endocr Relat Cancer 18: 301-10, 2011.
    • (2011) Endocr Relat Cancer , vol.18 , pp. 301-310
    • Dong, X.1    Korch, C.2    Meinkoth, J.L.3
  • 31
    • 79955801797 scopus 로고    scopus 로고
    • Combined effects of all-trans-retinoic acid and trichostatin A on the induction of differentiation of thyroid carcinoma cells
    • Yuan GB, Kuang AR, Fan Q, Yu LB and Mi YX; Combined effects of all-trans-retinoic acid and trichostatin A on the induction of differentiation of thyroid carcinoma cells. Chin J Cancer 29: 379-84, 2010.
    • (2010) Chin J Cancer , vol.29 , pp. 379-384
    • Yuan, G.B.1    Kuang, A.R.2    Fan, Q.3    Yu, L.B.4    Mi, Y.X.5
  • 32
    • 0036910932 scopus 로고    scopus 로고
    • Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor
    • Zarnegar R, Brunaud L, Kanauchi H, Wong M, Fung M, Ginzinger D, Duh QY and Clark OH: Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor. Surgery 132: 984-90, 2002.
    • (2002) Surgery , vol.132 , pp. 984-990
    • Zarnegar, R.1    Brunaud, L.2    Kanauchi, H.3    Wong, M.4    Fung, M.5    Ginzinger, D.6    Duh, Q.Y.7    Clark, O.H.8
  • 34
    • 50049117726 scopus 로고    scopus 로고
    • Suberoyl bishydroxamic acid activates notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma
    • Ning L, Jaskula-Sztul R, Kunnimalaiyaan M and Chen H: Suberoyl bishydroxamic acid activates notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma. Ann Surg Oncol 15: 2600-2605, 2008.
    • (2008) Ann Surg Oncol , vol.15 , pp. 2600-2605
    • Ning, L.1    Jaskula-Sztul, R.2    Kunnimalaiyaan, M.3    Chen, H.4
  • 35
    • 84991825469 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors: Updated studies in various epigenetic-related diseases
    • Zwergel C, Stazi G, Valente S and Mai A: Histone deacetylase inhibitors: Updated studies in various epigenetic-related diseases. J Clin Epigenet 2: 1, 2016.
    • (2016) J Clin Epigenet , vol.2 , pp. 1
    • Zwergel, C.1    Stazi, G.2    Valente, S.3    Mai, A.4
  • 36
    • 79952932076 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs
    • Kim HJ and Bae SC: Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 3: 166-179, 2011.
    • (2011) Am J Transl Res , vol.3 , pp. 166-179
    • Kim, H.J.1    Bae, S.C.2
  • 38
    • 73849114072 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors induce thyroid cancer specific apoptosis through proteasomedependent inhibition of TRAIL degradation
    • Borbone E, Berlingieri MT, De Bellis F, Nebbioso A, Chiappetta G, Mai A, Altucci L and Fusco A: Histone deacetylase inhibitors induce thyroid cancer specific apoptosis through proteasomedependent inhibition of TRAIL degradation. Oncogene 29: 105-116, 2010.
    • (2010) Oncogene , vol.29 , pp. 105-116
    • Borbone, E.1    Berlingieri, M.T.2    De Bellis, F.3    Nebbioso, A.4    Chiappetta, G.5    Mai, A.6    Altucci, L.7    Fusco, A.8
  • 39
    • 73149115248 scopus 로고    scopus 로고
    • Targeting the RET pathway in thyroid cancer
    • Wells SA Jr. and Santoro M: Targeting the RET pathway in thyroid cancer. Clin Cancer Res 15: 7119-7123, 2009.
    • (2009) Clin Cancer Res , vol.15 , pp. 7119-7123
    • Wells, S.A.1    Santoro, M.2
  • 40
    • 17144379329 scopus 로고    scopus 로고
    • Familial medullary thyroid cancer clinical aspects and prognosis
    • Hyer SL, Newbold K and Harmer C: Familial medullary thyroid cancer clinical aspects and prognosis. Eur J Surg Oncol 31: 415-419, 2005.
    • (2005) Eur J Surg Oncol , vol.31 , pp. 415-419
    • Hyer, S.L.1    Newbold, K.2    Harmer, C.3
  • 41
    • 77953365033 scopus 로고    scopus 로고
    • Notch in the development of thyroid C-cells and the treatment of medullary thyroid cancer
    • Cook M, Yu XM and Chen H: Notch in the development of thyroid C-cells and the treatment of medullary thyroid cancer. Am J Transl Res 2: 119-125, 2010.
    • (2010) Am J Transl Res , vol.2 , pp. 119-125
    • Cook, M.1    Yu, X.M.2    Chen, H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.